Drug development for neurodegenerative diseases: role of PET

被引：5
作者：
Rinne, JO
机构：
[1] Turku PET Ctr, FIN-20521 Turku, Finland
[2] Turku Univ, Dept Neurol, Turku, Finland
来源：
ANNALS OF MEDICINE | 1999年 / 31卷 / 06期
关键词：
Alzheimer's disease; drugs; drug development; Parkinson's disease; positron emission tomography;
D O I：
10.3109/07853899908998803
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
There are few relevant animal models for neurodegenerative diseases to be used for human drug development. Most current drugs for neurodegenerative diseases act through different neurotransmitter systems. Positron emission tomography (PET) is a unique tool in the study of neurodegenerative diseases as it enables quantitative measurements of oxygen consumption, blood now, energy metabolism and functioning of various neurotransmitter systems. There are several possibilities in the use of PET in drug development. It is possible to radiolabel the drug itself or to study the effect of an unlabelled drug on blood now, energy metabolism or function of neurotransmitter systems. All these approaches have been used in drug development for neurodegenerative diseases. However, in spite of the important role of PET in pathophysiological studies of neurodegenerative diseases, thus far the versatile possibilities of PET in drug development for neurodegenerative diseases have not been fully exploited.
引用
收藏
页码：444 / 449
页数：6
相关论文
共 68 条
  • [1] [C-11] RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY IN PREVIOUSLY UNTREATED PATIENTS WITH PARKINSONS-DISEASE - INFLUENCE OF L-DOPA AND LISURIDE THERAPY ON STRIATAL DOPAMINE D-2-RECEPTORS
    ANTONINI, A
    SCHWARZ, J
    OERTEL, WH
    BEER, HF
    MADEJA, UD
    LEENDERS, KL
    [J]. NEUROLOGY, 1994, 44 (07) : 1325 - 1329
  • [2] REPRODUCIBILITY OF CEREBRAL GLUCOSE METABOLIC MEASUREMENTS IN RESTING HUMAN-SUBJECTS
    BARTLETT, EJ
    BRODIE, JD
    WOLF, AP
    CHRISTMAN, DR
    LASKA, E
    MEISSNER, M
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1988, 8 (04) : 502 - 512
  • [3] BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
  • [4] METABOLIC EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE IN HUMAN BRAIN - MEASURED BY POSITRON EMISSION TOMOGRAPHY
    BLIN, J
    PIERCEY, MF
    GIUFFRA, ME
    MOURADIAN, MM
    CHASE, TN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1994, 123 (1-2) : 44 - 51
  • [5] Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin, J
    Mazetti, P
    Mazoyer, B
    Rivaud, S
    BenAyed, S
    Malapani, C
    Pillon, B
    Agid, Y
    [J]. BRAIN, 1995, 118 : 1485 - 1495
  • [6] Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
    Bodick, NC
    Offen, WW
    Levey, AI
    Cutler, NR
    Gauthier, SG
    Satlin, A
    Shannon, HE
    Tollefson, GD
    Rasmussen, K
    Bymaster, FP
    Hurley, DJ
    Potter, WZ
    Paul, SM
    [J]. ARCHIVES OF NEUROLOGY, 1997, 54 (04) : 465 - 473
  • [7] ON AREAS OF TRANSITION BETWEEN ENTORHINAL ALLOCORTEX AND TEMPORAL ISOCORTEX IN THE HUMAN-BRAIN - NORMAL MORPHOLOGY AND LAMINA-SPECIFIC PATHOLOGY IN ALZHEIMERS-DISEASE
    BRAAK, H
    BRAAK, E
    [J]. ACTA NEUROPATHOLOGICA, 1985, 68 (04) : 325 - 332
  • [8] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES
    BRAAK, H
    BRAAK, E
    [J]. ACTA NEUROPATHOLOGICA, 1991, 82 (04) : 239 - 259
  • [9] DIFFERING PATTERNS OF STRIATAL F-18 DOPA UPTAKE IN PARKINSONS-DISEASE, MULTIPLE SYSTEM ATROPHY, AND PROGRESSIVE SUPRANUCLEAR PALSY
    BROOKS, DJ
    IBANEZ, V
    SAWLE, GV
    QUINN, N
    LEES, AJ
    MATHIAS, CJ
    BANNISTER, R
    MARSDEN, CD
    FRACKOWIAK, RSJ
    [J]. ANNALS OF NEUROLOGY, 1990, 28 (04) : 547 - 555
  • [10] STRIATAL D2 RECEPTOR STATUS IN PATIENTS WITH PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION, AND PROGRESSIVE SUPRANUCLEAR PALSY, MEASURED WITH C-11 RACLOPRIDE AND POSITRON EMISSION TOMOGRAPHY
    BROOKS, DJ
    IBANEZ, V
    SAWLE, GV
    PLAYFORD, ED
    QUINN, N
    MATHIAS, CJ
    LEES, AJ
    MARSDEN, CD
    BANNISTER, R
    FRACKOWIAK, RSJ
    [J]. ANNALS OF NEUROLOGY, 1992, 31 (02) : 184 - 192
1234567